生物标志物在射血分数保留心力衰竭诊疗中的价值  

The value of biomarkers in diagnosis and treatment of heart failure with preserved ejection fraction retention

作　　者：张真路[1] Zhang Zhenlu(Clinical Lab,Wuhan Asia Heart Hospital,Wuhan 430022,China)

机构地区：[1]武汉亚洲心脏病医院检验科,武汉430022

出　　处：《中华检验医学杂志》2023年第12期1224-1234,共11页Chinese Journal of Laboratory Medicine

摘　　要：射血分数保留的心力衰竭(HFpEF)是一种异质性疾病,其作为一种全身性综合征表现出不同的临床病程和预后状况,关键是目前常用HF治疗手段对其治疗的疗效不佳。针对HFpEF的诊疗,当下和未来我们是否应该把现有常用的标志物,如高敏肌钙蛋白和BNP/NT-proBNP应用好的基础上,把视野更多转向心脏外,特别是涉及心-肝-肺-肾等器官相互“串扰”的生物标志物。Heart failure with preserved ejection fraction(HFpEF)is a heterogeneous disease,and as a systemic syndrome,it presents different clinical course and prognosis.Currently,HF is not effective in its treatment.For the diagnosis and treatment of HFpEF,at present and in the future,should we focus more on the biomarkers involving the"crosstalk"between organs such as heart-liver-lung-kidney,based on the good application of existing commonly used markers,such as high-sensitivity troponin and BNP/NT-proBNP.

关 键 词：心力衰竭 射血分数保留的心力衰竭 生物标志物 心-肝-肺-肾等器官相互“串扰”的生物标志物 

分 类 号：R541.6[医药卫生—心血管疾病]